Rheumatoid Arthritis (RA) 
Introduction
R/A is a chronic inflammatory disease of the locomotors system that leads to substantial disability, loss of productivity and increased mortality (Tugwell P 1995 1 ).
It is the commonest form of inflammatory arthritis and affects about 1-3/%, of the population (Wordswrth P et al 1966 2 ). Nearly 90/% of patients with aggressive disease will become clinically disabled within 20 years.
The severity of RA emphasizes the need for an effective management plan. In the past the treatment of RA has been developed on the premise that the prognosis of the disease is generally good. Treatment was based on NSAID and disease modifying agents such as sulfasalazine and Methotrexate. But this approach has limited success in preventing joint destruction or improving long term outcome. In fact, up to 90% of patients with aggressive synovitis develop evidence of bone erosions within two years of diagnosis despite treatment (Sharp JF et al. 1991 3 ).
It was argued that introduction of slow acting antirheumatic drugs before the onset of articular damage retard the radiographic progression and joint damage in RA patients (Weinblatt, 1993 4 ). It was also observed that there was a considerable overlap in toxicity between NSAIDs and SAARDs. These inferences lead to invention of therapeutic approach for RA that involved Institution of SAARDS early in course of the disease.
A realization soon followed that the outcome of treatment with these agents was far from satisfactory. Short term remission rates are acceptable but not high. Short term remission rates are acceptable but not high. Break through relapses are common. Meaningful remission of RA is found to occur in less than 2% of patients taking different SAARDs at the end of three years (Haq SA, 2000 5 ). Considering the limitations of the currently available therapeutic options, attempts are continuing to recognize the ways in which these drugs are administered.
A combination of azathioprine plus methotrexate was compared with methotrexate alone and azathioprine alone in a series of patients who failed to respond to a single SAARD other than azathioprine or methotrexate. Both the combination and methotrexate alone proved superior to azathioprine alone, but the combination was not superior to MTX alone (Willkens RF et al. 1995 6 9 ). Kirwan reported that patients treated with Corticosteroids have an overall improvement in general well-being and functional capacity along with a reduction in radiographic progression (Kirwan JR, 1998 10 ).
In a survey of 207 rheumatologist by O'Dell and Case, 95-1%, respondents indicated that they used combination therapies to treat their patients (Jain R et al. 1992 11 ) and they reported that combination therapy is cost effective and more potential.
So the present study has been designed to see efficacy and toxicity of combination therapy with MTX, Chloroquine and low dose Prednisolone in the Treatment of RA & compare with that of MTX.
Hypothesis: Combination therapy with MTX, Chloroqunie and low dose Prednisolone is better than MTX alone.
Objectives: To establish the effects on short term outcome of the disease with adverse effects of triple combination therapy with MTX, Chloroqunie and low dose Prednisolone versus MTX alone.
Materials and Methods
This was an open, randomized, Prospective study which followed qualitative research method. Here all subjects were randomly selected in two groups. Combination therapy is even number and MTX group is odd number in random table respectively. The present study was conducted in the Rheumatology wing of the department of medicine, Bangladesh Bangabandhu Sheikh Mojib Medical University, Dhaka. Bangladesh from September 1999 to September 2000 including a 6 months follow up. 61 Samples (RA Patients) were purposively selected to conduct the study. After collecting data were checked thoroughly for constancy and completeness. Data were checked to exclude any error or inconsistency.
All analysis was done by appropriate statistical methods using spss are software for windows. All ethical issues, which were related the research involved with human subject were followed according to the guideline of ethical review committee.
Results
All Subjects (61 Patients) were randomly selected to Combination Therapy and MTX group. One Patient from each group left the study. Finally 59 Patients Completed the study. 33 belonged to combination therapy group and 26 to MTX group. The age of the patient ranged from 16-70 years. 45 were female and 14 were male patients.
ORIGINAL ARTICLE
The two groups were nearly identical with respect to demography, clinical and laboratory parameters and sex ratio 3.06:1 (table-1). The differences between the two group was not statistically significant (table II) . Chi-square test with (yates correction) p=0.065 (p>0.05)
Discussion
Methotrexate is a well known established, widely prescribed disease modifying anti-rheumatic drug (DMARD) used for rheumatoid arthritis and considered as the good standard treatment of rheumatoid arthritis.
Forequent failure of treatment to halt the disease progression has encouraged rheumatologists to explore the possibility of other modes of treatment. Such alternative approaches (Willkens RF et al. 1992 12 ) are (1) use of second line agents (2) use of new drugs such as cyclosporine (3) use of biologic agents and (4) combined use of drugs with proven efficacy. Combination therapy is the easiest of these alternatives. Because rheumatologists have experiences with multiple drugs regimens (Willkens RF et al. 1992 12 ).
The present study partly fulfilled this approach. The present study was a randomized controlled prospective open clinical trail to see the efficacy and toxicity of combination therapy with MTX plus chloroquine plus low dose prednisolone on the activities of RA in comparison with MTX alone an established disease modifying agent. In the present study, there were 46 female and 15 male with a ratio of 3.06:1. This ratio can be compared with the sex ratio of 2.83:1 in the series of Willkens et al. 1992 12 .
In this seriest, the average age of patients of combination theraphy was 37.09±10.67 years and in the MTX group 33.81±10.88 yrs. In the study of Isalm MN et al. Willkens et al. 1992 . The discrepancy could be due to long survival in western population.
ORIGINAL ARTICLE
Prior to analysis different characteristics in both groups were compared to find out whether they had any statistically significant difference. The mean age, duration of illness, number of swollen joints, joint swelling index, joint pain, patients global assessment of disease activity, physicians global assessment of disease activity and ESR varied numerically between the two groups, but the differences were not statistically significant as in the study of Lopez Mendez et.al. 1991 15 .
When we compared combined group with that of MTX alone, in respect to the response of treatment after 6 months, most of the clinical and laboratory parameters did not show statistically significant difference between the two groups. .
We followed WHO/ILAR (Furst DE et.al.1994 18 ) response criteria and found that 23 (69.7%) patients were responded in combined group in comparison to 11 (42.30%) patients responded in the MTX group. The difference was no statistically significant P>0.05.
The actual Present situations of RA Patients Management in Bangladesh are not so pleasurable. The RA is mainly managed by MTX and disease modifying anti-rheumatic drug (DMARD). These are effective in the treatment of RA. But complete remission of RA is rare. So now the high time to think about alternative management of RA like as triple therapy with MTX, Chlorquine and low dose prednisolone.
Conclusion
The efficacy and tolerability of combination therapy with MTX plus chloroquine and low dose prednisolone was compared with the those of MTX in an open, random, controlled, prospective clinical trial. 61 patients were included in the study. 59 patients completed the trial with a 6 months follow up. 33 patients completed the trial in the combined group and 26 patients in the MTX group alone. One patient from each group dropped out due to adverse effects of drug. Statistically significant improvement was observed in almost all clinical and laboratory parameters in both groups. Compared with the MTX group, the combination therapy though did not show higher efficacy over MTX group alone but higher response rate (69.70%) was observed on the WHO/ILAR response criteria and 42.30% in MTX group. Combination therapy was tolerable and short term side effects were almost equal in two groups. Most common side effects observed were nausea and anorexia followed by dizziness in both groups.
